247568-67-8

Basic information

• Product Name: N-(3,4-DiMethoxybenzyl)-2-fluoro-5-nitrobenzaMide
• Synonyms: N-(3,4-DiMethoxybenzyl)-2-fluoro-5-nitrobenzaMide;5-DespropanolaMine-5-fluoro Xanthoanthrafil;N-[(3,4-DiMethoxyphenyl)Methyl]-2-fluoro-5-nitro-benzaMide
• CAS NO: 247568-67-8
• Molecular Formula: C₁₆H₁₅FN₂O₅
• Molecular Weight: 334.2991032
• Product Categories: Amines;Aromatics;Inhibitors;Amines, Aromatics, Inhibitors
• Mol File: 247568-67-8.mol

Chemical Properties

• Boiling Point: 490.0±45.0 °C(Predicted)
• Appearance: /
• Density: 1.313±0.06 g/cm3(Predicted)
• Storage Temp.: Refrigerator
• Solubility: Dichloromethane
• PKA: 12.18±0.46(Predicted)
• CAS DataBase Reference: N-(3,4-DiMethoxybenzyl)-2-fluoro-5-nitrobenzaMide(CAS DataBase Reference)
• NIST Chemistry Reference: N-(3,4-DiMethoxybenzyl)-2-fluoro-5-nitrobenzaMide(247568-67-8)
• EPA Substance Registry System: N-(3,4-DiMethoxybenzyl)-2-fluoro-5-nitrobenzaMide(247568-67-8)

Safety Data

• Hazardous Substances Data: 247568-67-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
N-(3,4-DiMethoxybenzyl)-2-fluoro-5-nitrobenzaMide is used as a chemical intermediate for the preparation of anthranilamides. These anthranilamides act as cGMP phosphodiesterase inhibitors, playing a crucial role in the development of potential therapeutic agents for various diseases and conditions. The inhibition of cGMP phosphodiesterase can lead to increased levels of cGMP, which is an important second messenger in cellular signaling pathways, and can have beneficial effects on various physiological processes.

Upstream product

• 7304-32-7 2-fluoro-5-nitrobenzoic acid 
• 5763-61-1 3,4-dimethoxybenzylamine 

Downstream Products

• 247568-77-0 2-[1-(tert-butoxycarbonyl)piperidin-4-ylamino]-N-(3,4-dimethoxybenzyl)-5-nitrobenzamide 
• 247567-43-7 (S)-N-(3,4-Dimethoxybenzyl)-2-[1-(hydroxymethyl)-propylamino]-5-nitrobenzamide 
• 247567-59-5 2-(1H-Benzimidazol-5-ylamino)-N-(3,4-dimethoxybenzyl)-5-nitrobenzamide 
• 247567-49-3 N-(3,4-Dimethoxylbenzyl)-2-{[(1R,2S)-cis-2,3-dihydro-2-hydroxy-1H-inden-1-yl]amino}-5-nitrobenzamide 
• 247568-91-8 N-(3,4-dimethoxybenzyl)-5-nitro-2-(piperidin-3-ylamino)benzamide hydrochloride 
• 247568-92-9 N-(3,4-Dimethoxybenzyl)-2-[1-(methanesulfonyl)piperidin-3-ylamino]-5-nitrobenzamide 
• 247567-58-4 N-(3,4-Dimethoxybenzyl)-2-(1-formylpiperidin-3-ylamino)-5-nitrobenzamide 
• 247568-93-0 N-(3,4-dimethoxybenzyl)-5-nitro-2-(piperidin-3-ylamino)benzamide 
• 247568-78-1 N-(3,4-dimethoxybenzyl)-5-nitro-2-(4-piperidinylamino)benzamide 
• 247568-83-8 N-(3,4-dimethoxylbenzyl)-2-[(R)-1-methoxycarbonyl-3-(methylthio)propylamino]-5-nitrobenzamide 
• 247567-50-6 N-(3,4-Dimethoxylbenzyl)-2-[(1R,2S)-2-hydroxy-1-methyl-2-phenylethyl]amino-5-nitrobenzamide 
• 247567-51-7 2-[(1S,2R)-1-(Carbamoyl)-2-hydroxypropylamino]-N-(3,4-dimethoxybenzyl)-5-nitrobenzamide 
• 247567-48-2 N-(3,4-Dimethoxybenzyl)-5-nitro-2-[2-(2,2,2-trifluoroethyl)hydrazino]benzamide 
• 247567-47-1 (S)-N-(3,4-Dimethoxybenzyl)-2-(2-hydroxy-1-methyl-ethylamino)-5-nitrobenzamide 

Relevant articles and documents

Anthranilic acid derivatives as inhibitors of the cGMP-phosphodiesterase

Compounds of formula (I) STR1where R 1 is hydrogen; R 2 is nitro, cyano or halo(lower)alkyl; R 3 is phenyl substituted with one or more substituents selected from halogen, cyano and lower alkoxy; A is a lower alkylene group; R 4 is a group CR 6 R 7 R 8 wherein R 6 and R 7 form, together with the carbon atom to which they are attached a cycloalkyl group optionally substituted with hydroxy, lower alkoxy or a lower alkanoylamino; and R 8 is hydrogen; its prodrug and a salt thereof.